Ignite Creation Date:
2024-05-06 @ 9:24 AM
Last Modification Date:
2024-10-26 @ 12:14 PM
Study NCT ID:
NCT02978716
Status:
TERMINATED
Last Update Posted:
2022-03-23
First Post:
2016-11-18
Brief Title:
Trilaciclib G1T28 a CDK 46 Inhibitor in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer mTNBC
Sponsor:
G1 Therapeutics Inc
Organization:
G1 Therapeutics Inc
Organization Data
Organization:
G1 Therapeutics Inc
Class:
INDUSTRY
Study ID:
G1T28-04
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
G1 Therapeutics Inc
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None